Featured Education

Playlist

3 Videos

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Weight Management as a Treatment for T2D: Novel Pharmacological Approaches
  • Credit: 0.50hr(s)
  • AAFP, AAPA, ABIM, CME, IPCE, MOC
  • April 30, 2024 — 
  • October 31, 2025
  • Therapeutic Areas: Diabetes, Family Medicine / Primary Care, Obesity
  • Specialties: Diabetes, Endocrinology, Obesity, Primary Care
  • Location: Internet Activity Enduring
Healthcare providers (HCPs) encounter significant challenges when treating patients with type 2 diabetes (T2D). HCPs should be cognizant of when to change or intensify treatment and be aware of options that are non-optimal. As such, HCPs need to be equipped with current professional guidelines, the latest clinical evidence on new and emerging therapies for T2D, and strategies for engaging patients in shared decision-making to effectively prioritize weight management and promote comprehensive T2D care.
Access Course
  • On-Demand
Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies
  • Credit: 0.50hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this second episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty on how to select CAR T-cell and bispecific antibody treatment regimens for NHL according to the latest clinical evidence including safety and efficacy data in accordance with clinical guidelines. Additionally, expert faculty will discuss how to best identify patients who are candidates for CAR T-cell or bispecific antibody therapies as well as how to evaluate the potential of bridging therapy in patients awaiting CAR T-cell therapy. Finally, expert faculty will review treatment-related toxicities with strategies and educational tools that can be used to prevent, monitor, and manage adverse events. This episode will conclude with a discussion between expert faculty and a special guest, Caitlin Murphy, DNP.
Access Course
  • On-Demand
The Evolution of HCT, Part 3: Donor Availability
  • Credit: 0.75hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 3 in a 5-part series, covering advances in donor availability that have led to expanded access to HCT over time.
Access Course
  • On-Demand
The Evolution of HCT, Part 1: Basics and Outcomes
  • Credit: 1.50hr(s)
  • CME, NCPD
  • February 22, 2024 — 
  • February 20, 2025
  • Therapeutic Areas: Hematologic Oncology, Hematology, Hematopoietic Cell Transplantation (HCT), Oncology
  • Specialties: Bone Marrow Transplantation, Hematology, Oncology
  • Location: Internet Activity Enduring
Community hematology/oncology practices play a critical role to expand patient access to hematopoietic cell transplantation (HCT) and improve patient outcomes. This self-guided online training course series consists of five courses designed to present the current state of the science for Hematopoietic Cell Transplantation (HCT) by following the evolution of HCT over time. The series is broken down into major misperceptions or myths about HCT and cellular therapy that are not supported by current research and clinical practice. This is Part 1 in a 5-part series, including the series introduction, basics of HCT, and major advances in HCT outcomes over time.
Access Course
  • On-Demand
Beyond Inertia: Advancing T2D Care With Innovative Basal Insulin Strategies
  • Credit: 1.50hr(s)
  • CME, CPE, NCPD, PA
  • June 21, 2024 — 
  • June 20, 2025
  • Therapeutic Areas: Diabetology, Endocrinology
  • Specialties: Endocrinology, Primary Care
  • Location: Internet Activity Enduring
Discover the forefront of diabetes care at Diabetes Dialogues LIVE, targeting the latest in once-weekly basal insulin therapy, including unique mechanism of action and pharmacokinetic/pharmacodynamic properties. Join fellow endocrinologists to unpack recent safety and efficacy data. Additionally, hear discussion about basal insulin therapy for patient care and how to best ensure adherence through effective T2D management. Delve into clinical trials outcomes, glycemic control, weight management, and hypoglycemia risks. Engage in essential scientific discourse to shape the future of diabetes treatment. Do not miss this event for an insightful blend of data and practice. This activity is derived from the Live ISS Meeting at ENDO, originally held on June 1, 2024.
Access Course
  • On-Demand
New Horizons in Multiple Myeloma Treatment: The Promise of CAR-T for Early Relapsed Disease
  • Credit: 1.00hr(s)
  • AAPA, CME, CPE, IPCE, NCPD
  • May 31, 2023 — 
  • May 30, 2024
  • Therapeutic Areas: Hematologic Oncology, Hematology, Oncology
  • Specialties: CAR T-Cell Therapy, Multiple Myeloma
  • Location: Internet Activity Enduring
Despite remarkable progress, significant gaps remain in meeting the needs of patients facing relapse in multiple myeloma, particularly among patients with early relapse or triple-class exposed disease. Join us for a groundbreaking Special Edition Med Table Talk episode where we delve into the latest advancements in the treatment of relapsed multiple myeloma (RRMM).  This candid conversation between esteemed faculty experts discusses the latest clinical evidence and rationale for CAR T-cell therapy in early versus late relapse settings and embraces a future pathway where highly effective treatments may be delivered earlier to support increasingly durable responses for complex patient populations.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top